Latest news with #VRTX
Yahoo
5 days ago
- Business
- Yahoo
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.68% at $440.87. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow gained 0.08%, and the Nasdaq, a tech-heavy index, lost 0.51%. Heading into today, shares of the drugmaker had gained 3.31% over the past month, outpacing the Medical sector's loss of 0% and the S&P 500's gain of 0.45%. The investment community will be paying close attention to the earnings performance of Vertex Pharmaceuticals in its upcoming release. It is anticipated that the company will report an EPS of $4.24, marking a 133.05% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $2.88 billion, showing a 8.85% escalation compared to the year-ago quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $17.82 per share and revenue of $11.91 billion. These totals would mark changes of +4142.86% and +8.06%, respectively, from last year. It is also important to note the recent changes to analyst estimates for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.08% higher. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that Vertex Pharmaceuticals has a Forward P/E ratio of 25.17 right now. This represents a premium compared to its industry average Forward P/E of 19.86. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 36% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
1 Large-Cap Stock to Target This Week and 2 to Question
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players. This dynamic can trouble even the most skilled investors, but luckily for you, we started StockStory to help you navigate these trade-offs and uncover exceptional companies that break the mold. That said, here is one large-cap stock that still has big upside potential and two that could be stalling. Market Cap: $196.7 billion Founded by Alexander Graham Bell, AT&T (NYSE:T) is a multinational telecomm conglomerate providing a range of communications and internet services. Why Do We Think T Will Underperform? Annual sales declines of 7.3% for the past five years show its products and services struggled to connect with the market Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 10.9% annually, worse than its revenue ROIC of 3.3% reflects management's challenges in identifying attractive investment opportunities AT&T is trading at $27.30 per share, or 13.1x forward P/E. Read our free research report to see why you should think twice about including T in your portfolio, it's free. Market Cap: $111.5 billion Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ:VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management. Why Are We Wary of VRTX? Earnings per share fell by 15.6% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 58.8 percentage points Waning returns on capital imply its previous profit engines are losing steam At $440 per share, Vertex Pharmaceuticals trades at 23.4x forward P/E. If you're considering VRTX for your portfolio, see our FREE research report to learn more. Market Cap: $38.32 billion Originally serving yogis and hockey players, Lululemon (NASDAQ:LULU) is a designer, distributor, and retailer of athletic apparel for men and women. Why Should You Buy LULU? Locations open for at least a year are seeing increased demand as same-store sales have averaged 8.2% growth over the past two years Collection of products is difficult to replicate at scale and results in a best-in-class gross margin of 58.8% Robust free cash flow margin of 16% gives it many options for capital deployment Lululemon's stock price of $318.96 implies a valuation ratio of 20.8x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
13-05-2025
- Business
- Yahoo
This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next
Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. The company tends to run up after significant price drops. Vertex's business and prospects remain attractive. 10 stocks we like better than Vertex Pharmaceuticals › Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update. The results were not to the market's liking, so much so that they led to a significant post-earnings dip for the stock. Shares are still in the green year to date, but only barely. However, Vertex's past stock-market meltdowns -- and what happened afterward -- might suggest that its most recent drop represents an excellent buying opportunity. Let's review some reasons that led to Vertex Pharmaceuticals' post-earnings dip. First, the company's financial results were not as strong as expected: It missed revenue and earnings estimates. Second, the biotech announced a clinical setback. It decided to pause the development of VX-522, a next-gen, mRNA-based therapy for cystic fibrosis (CF), due to potential tolerability issues. Vertex famously dominates the CF area, and its current medicines can treat about 90% of patients with this rare disease. It was developing VX-522 for some patients who are not eligible for the existing standards of care, but the medicine's future is now uncertain. With that out of the way, let's review how Vertex's shares have reacted after double-digit plunges in the past five years. Back in 2020, the company announced it would give up the development of VX-814, a potential treatment for alpha-1 antitrypsin deficiency (AATD), a rare disease that can cause lung and liver damage. Vertex's shares fell off a cliff following this announcement on Oct. 14, 2020, but they bounced back big-time thereafter: More recently, on Dec. 19, Vertex announced phase 2 results for suzetrigrine (marketed as Journavx in treating acute pain) in patients with painful lumbosacral radiculopathy. The data was positive, or so said the company. Wall Street disagreed, sending Vertex's shares down significantly. Once again, the stock rebounded admirably, at least until its most recent dip. And even considering this post-earnings decline, Vertex's shares have outperformed broader equities since that debacle: Of course, these examples don't guarantee the same thing will happen this time, but there are good reasons beyond the historical record to believe it will. Let's dig deeper into Vertex's Q1 update. Its results did miss analyst projections, partly because of copies of its CF medicine in Russia that ate into its revenue and earnings. Vertex Pharmaceuticals believes this issue is isolated to Russia, and that even there the company should be able to solve it eventually, since these are illegal copies. What about the recent clinical setback? The worst-case scenario would be for the drugmaker to abandon the development of VX-522. We don't know if this will happen yet, but if it does, it wouldn't be the first time one of its CF therapies fails a study. Developing medicines that address the underlying causes of this rare condition is challenging; that's why no biotech company has been able to do it except for Vertex Pharmaceuticals. Even if this one fails, the company's significant experience in this area suggests that it will eventually crack the code for patients who are currently ineligible for its existing drugs. It has developed newer medicines with broader patient populations multiple times in the past 10 years. Of note, Vertex also took a $379 million impairment charge in the first quarter that affected its bottom line, due to its decision to give up development of VX-264, an investigational therapy for type 1 diabetes (T1D). But the issues that led to Vertex's poor first-quarter results are temporary. It has excellent long-term prospects, as its CF lineup is still going strong. The recent addition of Alyftrek -- a newer CF therapy -- to its portfolio should eventually make a meaningful impact. The company's other products, Casgevy (which treats two rare blood diseases) and Journavx, should also meaningfully contribute to top-line growth. Vertex's pipeline features VX-880, another medicine being developed for T1D; given this therapy's progress, Vertex expects regulatory submissions in 2026. Elsewhere, it is working on potential breakthrough drugs such as inaxaplin, which could become the first medicine that targets the underlying causes of a condition called APOL-1 mediated kidney disease. With all that going on, Vertex Pharmaceuticals should still perform well in the long run. Its shares look like a no-brainer buy on the dip. Before you buy stock in Vertex Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vertex Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $614,911!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $714,958!* Now, it's worth noting Stock Advisor's total average return is 907% — a market-crushing outperformance compared to 163% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next was originally published by The Motley Fool
